Moreover, SCAD siRNA treatment triggered the same pathological hypertrophy as cardiomyocytes treated with PE, which showed that the down-regulation of SCAD expression played an important role in pathological cardiac hypertrophy. The gene discussed is ACADS; the disease is cardiac hypertrophy.